

Plasma cell and B cell-targeted treatments for use in ad

Multiple Sclerosis and Related Disorders
35, 19-25

DOI: [10.1016/j.msard.2019.06.030](https://doi.org/10.1016/j.msard.2019.06.030)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epstein-Barr virus infection in the development of neurological disorders. <i>Drug Discovery Today: Disease Models</i> , 2020, 32, 35-52.	1.2	26
2	B cells and multiple sclerosis spinal cord pathology. <i>Brain Pathology</i> , 2020, 30, 730-731.	4.1	0
3	Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103264.	2.0	20
4	Dare we mention the C-word?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102340.	2.0	0
5	Neural stem cell engineering for the treatment of multiple sclerosis. <i>Biomedical Engineering Advances</i> , 2022, 4, 100053.	3.8	0
6	Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study. <i>Journal of Neurology</i> , 2023, 270, 272-282.	3.6	6
7	Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients. <i>Brain Sciences</i> , 2022, 12, 1595.	2.3	3
8	What are T-cells telling us about how EBV causes MS?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104434.	2.0	3
9	Are we ready for CD19-targeted CAR T-cell therapies in MS?. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104590.	2.0	1
10	Sphingosylphosphorylcholine inhibits plasma cell differentiation and ameliorates experimental autoimmune encephalomyelitis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
11	Beyond the B-cell as a treatment target in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 75, 104786.	2.0	0
12	The pathogenesis of multiple sclerosis: a series of unfortunate events. <i>Clinical and Experimental Immunology</i> , 0, , .	2.6	0
13	Targeting Epstein-Barr virus in multiple sclerosis: when and how?. <i>Current Opinion in Neurology</i> , 2024, 37, 228-236.	3.6	0